文献速递脑血管病

急性缺血性卒中早期与延迟他汀治疗随机对照试验(ASSORT)

Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient).
PubMed 文献 · Stroke · 2017-10-13

ASSORT 试验在日本 11 家医院纳入 257 例伴血脂异常的急性缺血性卒中患者,随机分为入院 24 小时内早期他汀组与第 7 天延迟他汀组,治疗 12 周。90 天改良 Rankin 量表分布两组无差异(P=0.68),早期组校正共同比值比 0.84(95%CI 0.53-1.3;P=0.46),未显示早期他汀优于延迟他汀。

要点

  • 急性缺血性卒中伴血脂异常者,入院 24 小时内启动他汀未改善 90 天残疾结局。
  • 早期组与延迟组 90 天 mRS 分布无差异,校正共同 OR 为 0.84(95%CI 0.53-1.3)。
  • 两组安全性相似,早期组卒中复发 9 例(6.9%),延迟组 5 例(4.0%)。

核心结论

  • 伴血脂异常的急性缺血性卒中患者中,入院 24 小时内早期他汀治疗相比第 7 天延迟治疗,未显示改善 90 天残疾程度的优势。

研究设计与样本

  • 多中心、开放标签、随机对照试验,在日本 11 家医院开展。
  • 257 例急性缺血性卒中伴血脂异常患者按 1:1 随机分为早期组(131 例)与延迟组(126 例)。
  • 早期组入院 24 小时内给药,延迟组第 7 天给药,他汀疗程均为 12 周。

主要发现

  • 90 天改良 Rankin 量表评分分布两组无差异(P=0.68)。
  • 早期组校正共同比值比为 0.84(95%CI 0.53-1.3;P=0.46),对照为延迟他汀组。
  • 90 天共 3 例死亡(早期组 2 例、延迟组 1 例),均因恶性肿瘤。
  • 缺血性卒中复发:早期组 9 例(6.9%),延迟组 5 例(4.0%)。
  • 两组安全性特征相似。

关键数值与推荐

  • 主要结局为 90 天改良 Rankin 量表评估的残疾程度。
  • 早期他汀定义为入院 24 小时内给药,延迟他汀定义为入院第 7 天给药。
  • 他汀治疗持续 12 周;随机比例为 1:1。

临床怎么用

  • 对伴血脂异常的急性缺血性卒中患者,无需为改善 90 天残疾结局而在入院 24 小时内紧急启动他汀。
  • 入院后第 7 天启动他汀在本试验中未显示劣于早期启动,具体时机可结合个体情况决定。
  • 本试验样本量有限,治疗决策仍需参考更大规模证据与指南。

局限性

  • 开放标签设计,未设盲。
  • 样本量较小,共 257 例,检验效能有限。
  • 仅纳入日本伴血脂异常的急性缺血性卒中患者,外推需谨慎。
  • 随访主要终点为 90 天,未评估更长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Several studies suggested that statins during hospitalization were associated with better disability outcomes in patients with acute ischemic stroke, but only 1 small randomized trial is available. METHODS: We conducted a multicenter, open-label, randomized controlled trial in patients with acute ischemic strokes in 11 hospitals in Japan. Patients with acute ischemic stroke and dyslipidemia randomly received statins within 24 hours after admission in the early group or on the seventh day in the delayed group, in a 1:1 ratio. Statins were administered for 12 weeks. The primary outcome was patient disability assessed by modified Rankin Scale at 90 days. RESULTS: A total of 257 patients were randomized and analyzed (early 131, delayed 126). At 90 days, modified Rankin Scale score distribution did not differ between groups (P=0.68), and the adjusted common odds ratio of the early statin group was 0.84 (95% confidence interval, 0.53-1.3; P=0.46) compared with the delayed statin group. There were 3 deaths at 90 days (2 in the early group, 1 in the delayed group) because of malignancy. Ischemic stroke recurred in 9 patients (6.9%) in the early group and 5 patients (4.0%) in the delayed group. The safety profile was similar between groups. CONCLUSIONS: Our randomized trial involving patients with acute ischemic stroke and dyslipidemia did not show any superiority of early statin therapy within 24 hours of admission compared with delayed statin therapy 7 days after admission to alleviate the degree of disability at 90 days after onset. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02549846.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yoshimura S, Uchida K, Daimon T, et al. Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient). Stroke. 2017. PMID: 29030478. doi:10.1161/STROKEAHA.117.017623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。